235
Views
2
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Correlation Between Mean Amplitude of Glycemic Excursion and Bone Turnover Markers in Patients with Type 2 Diabetes: A Cross-Sectional Study

, , , &
Pages 397-407 | Received 09 Sep 2022, Accepted 13 Jan 2023, Published online: 10 Feb 2023

References

  • Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA. 2011;305(21):2184–2192. doi:10.1001/jama.2011.715
  • Wang H, Ba Y, Xing Q, et al. Diabetes mellitus and the risk of fractures at specific sites: a meta-analysis. BMJ Open. 2019;9(1):e24067.
  • Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes--a meta-analysis. Osteoporos Int. 2007;18(4):427–444. doi:10.1007/s00198-006-0253-4
  • Janghorbani M, Van Dam RM, Willett WC, et al. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505. doi:10.1093/aje/kwm106
  • Gregg EW, Beckles GL, Williamson DF, et al. Diabetes and physical disability among older U.S. adults. Diabetes Care. 2000;23(9):1272–1277. doi:10.2337/diacare.23.9.1272
  • Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women’s Health Initiative Observational Study. J Clin Endocrinol Metab. 2006;91(9):3404–3410. doi:10.1210/jc.2006-0614
  • Manavalan JS, Cremers S, Dempster DW, et al. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(9):3240–3250. doi:10.1210/jc.2012-1546
  • Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014;29(4):787–795. doi:10.1002/jbmr.2106
  • Tanaka K, Yamaguchi T, Kanazawa I, et al. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun. 2015;461(2):193–199. doi:10.1016/j.bbrc.2015.02.091
  • Pacicca DM, Brown T, Watkins D, et al. Elevated glucose acts directly on osteocytes to increase sclerostin expression in diabetes. Sci Rep. 2019;9(1):17353. doi:10.1038/s41598-019-52224-3
  • Starup-Linde J, Lykkeboe S, Gregersen S, et al. Differences in biochemical bone markers by diabetes type and the impact of glucose. Bone. 2016;83:149–155. doi:10.1016/j.bone.2015.11.004
  • Xu F, Zhao LH, Su JB, et al. The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c. Diabetol Metab Syndr. 2014;6(1):139. doi:10.1186/1758-5996-6-139
  • Starup-Linde J, Lykkeboe S, Handberg A, et al. Glucose variability and low bone turnover in people with type 2 diabetes. Bone. 2021;153:116159. doi:10.1016/j.bone.2021.116159
  • Noble JJ. Declaration of Helsinki. DEAD BMJ. 2007;335(7623):736.
  • Draznin B, Aroda VR, Bakris G, et al. Summary of revisions: standards of medical care in diabetes-2022. Diabetes Care. 2022;45(Supplement_1):S4–S7.
  • Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247–254. doi:10.7326/0003-4819-145-4-200608150-00004
  • Monnier L, Colette C, Sardinoux M, et al. Frequency and severity of the Dawn phenomenon in type 2 diabetes: relationship to age. Diabetes Care. 2012;35(12):2597–2599. doi:10.2337/dc12-0385
  • Rausch JR. Measures of glycemic variability and links with psychological functioning. Curr Diab Rep. 2010;10(6):415–421. doi:10.1007/s11892-010-0152-0
  • Rong Huang HWZS. Increased glycemic variability evaluated by continuous glucose monitoring is associated with osteoporosis in type 2 diabetic patients. Front Endocrinol. 2022;13:861131.
  • Krege JH, Lane NE, Harris JM, et al. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporos Int. 2014;25(9):2159–2171. doi:10.1007/s00198-014-2646-0
  • Xu F, Ye YP, Dong YH, et al. Inhibitory effects of high glucose/insulin environment on osteoclast formation and resorption in vitro. J Huazhong Univ Sci Technol Med Sci. 2013;33(2):244–249. doi:10.1007/s11596-013-1105-z
  • Levinger I, Seeman E, Jerums G, et al. Glucose-loading reduces bone remodeling in women and osteoblast function in vitro. Physiol Rep. 2016;4(3):e12700. doi:10.14814/phy2.12700
  • Tanaka KI. [ASBMR topics from clinical research(osteoporosis and sarcopenia).]. Clin Calcium. 2019;29(1):112–115. Japanese.
  • Smith-Palmer J, Brandle M, Trevisan R, et al. Assessment of the association between glycemic variability and diabetes-related complications in type 1 and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(3):273–284. doi:10.1016/j.diabres.2014.06.007
  • Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288–298. doi:10.1111/j.1463-1326.2009.01160.x
  • Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–2369. doi:10.2337/dc15-1188
  • Tanko LB, Christiansen C, Cox DA, et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res. 2005;20(11):1912–1920. doi:10.1359/JBMR.050711
  • Compston JE, Laskey MA, Croucher PI, et al. Effect of diet-induced weight loss on total body bone mass. Clin Sci. 1992;82(4):429–432. doi:10.1042/cs0820429
  • Andersen RE, Wadden TA, Herzog RJ. Changes in bone mineral content in obese dieting women. Metabolism. 1997;46(8):857–861. doi:10.1016/S0026-0495(97)90070-6
  • Jensen LB, Kollerup G, Quaade F, et al. Bone minerals changes in obese women during a moderate weight loss with and without calcium supplementation. J Bone Miner Res. 2001;16(1):141–147. doi:10.1359/jbmr.2001.16.1.141
  • Anhe FF, Barra NG, Schertzer JD. Glucose alters the symbiotic relationships between gut microbiota and host physiology. Am J Physiol Endocrinol Metab. 2020;318(2):E111–E116. doi:10.1152/ajpendo.00485.2019
  • Cheng B, Wen Y, Yang X, et al. Gut microbiota is associated with bone mineral density: an observational and genome-wide environmental interaction analysis in the UK Biobank cohort. Bone Joint Res. 2021;10(11):734–741. doi:10.1302/2046-3758.1011.BJR-2021-0181.R1
  • Qin Q, Yan S, Yang Y, et al. The relationship between osteoporosis and intestinal microbes in the Henan Province of China. Front Cell Dev Biol. 2021;9:752990. doi:10.3389/fcell.2021.752990
  • Liu R, Chao A, Wang K, et al. Incidence and risk factors of medical complications and direct medical costs after osteoporotic fracture among patients in China. Arch Osteoporos. 2018;13(1):12. doi:10.1007/s11657-018-0429-5
  • Domazetovic V, Fontani F, Marcucci G, et al. Estrogen inhibits starvation-induced apoptosis in osteocytes by a redox-independent process involving association of JNK and glutathione S-transferase P1-1. FEBS Open Bio. 2017;7(5):705–718. doi:10.1002/2211-5463.12216
  • Guo L, Chen K, Yuan J, et al. Estrogen inhibits osteoclasts formation and bone resorption via microRNA-27a targeting PPARgamma and APC. J Cell Physiol. 2018;234(1):581–594. doi:10.1002/jcp.26788
  • Chen Q, Kaji H, Sugimoto T, et al. Testosterone inhibits osteoclast formation stimulated by parathyroid hormone through androgen receptor. FEBS Lett. 2001;491(1–2):91–93. doi:10.1016/S0014-5793(01)02160-3
  • Rianon NJ, Smith SM, Lee M, et al. Glycemic control and bone turnover in older Mexican Americans with type 2 diabetes. J Osteoporos. 2018;2018:7153021. doi:10.1155/2018/7153021
  • Kulkarni SV, Meenatchi S, Reeta R, et al. Association of glycemic status with bone turnover markers in type 2 diabetes mellitus. Int J Appl Basic Med Res. 2017;7(4):247–251. doi:10.4103/ijabmr.IJABMR_35_17
  • Colleluori G, Aguirre L, Dorin R, et al. Hypogonadal men with type 2 diabetes mellitus have smaller bone size and lower bone turnover. Bone. 2017;99:14–19. doi:10.1016/j.bone.2017.03.039
  • Thornton JD, Saunders R, Lian J, Karolicki B, Valentine W. The cost-effectiveness and budget impact of stepwise addition of bolus insulin in the treatment of type 2 diabetes: evaluation of the FullSTEP trial. J Med Econ. 2014;17(12):827–836. doi:10.3111/13696998.2014.959590